Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Upfront Carfilzomib, Lenalidomide, Dexamethasone with Transplant in Multiple Myeloma Patients, the IFM KRd final results

Clinical Trials & Observations

Murielle Roussel, Valerie Lauwers-Cances, Soraya Wuilleme, Karim Belhadj, Salomon Manier, Laurent Garderet, Martine Escoffre-Barbe, Slara Mariette, Lotfi Benboubker, Denis Caillot, Cécile Sonntag, Cyrille Touzeau, Jehan Dupuis, Philippe Moreau, Xavier Leleu, Thierry Facon, Benjamin Hébraud, Jill Corre, Michel Attal

Blood blood.2021010744.

DOI: https://doi.org/10.1182/blood.2021010744

Published: 2021

Journal Articles

del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma

Clinical Trials & Observations Brief Report

Blood (2021) 137 (9): 1192–1195.

DOI: https://doi.org/10.1182/blood.2020008346

Published: 2021

Includes: Supplemental data

Journal Articles

Risk factors in multiple myeloma: is it time for a revision?

Jill Corre, Nikhil C. Munshi, Hervé Avet-Loiseau

Blood (2021) 137 (1): 16–19.

DOI: https://doi.org/10.1182/blood.2019004309

Published: 2021

Journal Articles

Undetectable MRD can change the deal

Jill Corre

Blood (2021) 137 (1): 5–6.

DOI: https://doi.org/10.1182/blood.2020008090

Published: 2021

Journal Articles

Longitudinal Immunogenomic Profiling of Tumor and Immune Cells for Minimally-Invasive Monitoring of Smoldering Multiple Myeloma (SMM): The Immunocell Study

Rosalinda Termini, Evangelos Terpos, MDPhD, Albert Pérez, MD, Tomas Jelinek, Nikoletta-Aikaterini Kokkali, Joan Bargay, MD, Fernando Solano Ramos, MD PhD, Sara Rodríguez, PhD, Cristina Pérez Ruiz, Catarina Maia, Antonio Sacco, RN, Marco Chiarini, MSc, Viviana Giustini, MSc, Jill Corre, PharmD, PhD, Francois Vergez, DVM, PhD, Marc S. Raab, MD, Niels Weinhold, PhD, Aitziber Lopez Lopez, Sonia Garate, Diego Alignani, PhD, Sarvide Sarai, Remco Loos, Antoni Garcia-Guiñon, MD, Maialen Sirvent, José Enrique de la Puerta, Rebeca Iglesias, Maria Casanova, MD, Maria Elena Cabezudo, Valentin Cabañas, MD, Enrique M. Ocio, MDPhD, Joaquin Martinez-Lopez, MD, Javier de la Rubia, Artur Paiva, Helena Vitoria, Catarina Geraldes, MD PhD, Roman Hajek, MD, Heinz Ludwig, MD, Hartmut Goldschmidt, MD, Herve Avet-Loiseau, Aldo M. Roccaro, MDPhD, Jesús F. San-Miguel, Bruno Paiva, PhD

Blood (2020) 136 (Supplement 1): 1–2.

DOI: https://doi.org/10.1182/blood-2020-136251

Published: 2020

Journal Articles

High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma

Mehmet K. Samur, PhD, Marco Roncador, MD MSc, Anil Aktas-Samur, PhD, Mariateresa Fulciniti, PhD, Abdul Hamid Bazarbachi, MD, Raphael Szalat, Masood A. Shammas, PhD, Adam S Sperling, MD PhD, Paul G. Richardson, MD, Florence Magrangeas, Stephane Minvielle, PhD, Anjan Thakurta, Aurore Perrot, Jill Corre, PharmD, PhD, Philippe Moreau, MD, Kenneth Anderson, MD, Giovanni Parmigiani, PhD, Herve Avet-Loiseau, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 4–5.

DOI: https://doi.org/10.1182/blood-2020-139014

Published: 2020

Journal Articles

High Throughput Genomic Analysis Identifies Low-Risk Smoldering Multiple Myeloma

Anil Aktas-Samur, PhD, Mariateresa Fulciniti, PhD, Sanika Derebail, MS, Raphael Szalat, Giovanni Parmigiani, PhD, Jill Corre, PharmD, PhD, Herve Avet-Loiseau, Mehmet K. Samur, PhD, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 2.

DOI: https://doi.org/10.1182/blood-2020-139066

Published: 2020

Journal Articles

The Genomic and Transcriptomic Landscape of Plasma Cell Leukemia

Titouan Cazaubiel, Laure Buisson, Sabrina Maheo, Laura Do Souto Ferreira, Romain Lannes, PhD, Aurore Perrot, Cyrille Hulin, MD, Hervé Avet-Loiseau, MD PhD, Jill Corre, PharmD, PhD

Blood (2020) 136 (Supplement 1): 48–49.

DOI: https://doi.org/10.1182/blood-2020-139340

Published: 2020

Journal Articles

Genomic and Transcriptomic Characterization of IgM Multiple Myeloma Identifies a Pre-Germinal Center Plasma Cell Disorder with Immature B-Cell Transcription-Factor Signature

Abdul Hamid Bazarbachi, MD, Herve Avet-Loiseau, Zachary R Hunter, PhD, Raphael Szalat, Anil Aktas-Samur, PhD, Masood A. Shammas, PhD, Jill Corre, PharmD, PhD, Mariateresa Fulciniti, PhD, Kenneth Anderson, MD, Giovanni Parmigiani, PhD, Steven Treon, Mohamad Mohty, MD PhD, Mehmet K. Samur, PhD, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 7–8.

DOI: https://doi.org/10.1182/blood-2020-138951

Published: 2020

Journal Articles

Minimal Residual Disease in Multiple Myeloma: Targeted Mass Spectrometry in Blood Vs Next Generation Sequencing in Bone Marrow

Marina Zajec, Pieter Langerhorst, Somayya Noori, Martijn van Duijn, Yolanda de Rijke, Jolein Gloerich, Alain van Gool, Jill Corre, PharmD, PhD, Thomas Dejoie, Helene Caillon, Joannes Jacobs, Theo Luider, Herve Avet-Loiseau

Blood (2020) 136 (Supplement 1): 9.

DOI: https://doi.org/10.1182/blood-2020-139330

Published: 2020

Journal Articles

The Discriminatory Ability of the R-ISS Is Equivalent to the ISS in a Large Cohort of Newly Diagnosed Multiple Myeloma (NDMM) Patients

Anaïs Schavgoulidze, Valerie Lauwers-Cances, Aurore Perrot, Herve Avet-Loiseau, Jill Corre, PharmD, PhD

Blood (2020) 136 (Supplement 1): 46–47.

DOI: https://doi.org/10.1182/blood-2020-136996

Published: 2020

Journal Articles

Crowded bone marrow plasma cells

Jill Corre, Murielle Roussel

Blood (2020) 135 (1): 79.

DOI: https://doi.org/10.1182/blood.2019003098

Published: 2020

Journal Articles

Gene Expression and Genomic Markers Identify a Subpopulation of Poor Prognosis t(4;14) Patients in Newly Diagnosed Multiple Myeloma

Maria Ortiz, Fadi Towfic, PhD, Erin Flynt, Nicholas Stong, PhD, Sneh Lata, PhD, Dharanya Sampath, Dan Rozelle, PhD, Matthew Trotter, PhD, Jill Corre, PharmD, PhD, Hervé Avet-Loiseau, MD PhD, Anjan Thakurta

Blood (2019) 134 (Supplement_1): 366.

DOI: https://doi.org/10.1182/blood-2019-128907

Published: 2019

Journal Articles

The Landscape of Genome Wide Somatic Alterations Identifies a Good-Risk Group in Newly Diagnosed Multiple Myeloma

Mehmet Kemal Samur, PhD, Anil Aktas Samur, PhD, Tessa Han, Marco Roncador, MD MSc, Mariateresa Fulciniti, PhD, Raphael Szalat, Masood A. Shammas, PhD, Jill Corre, PharmD, PhD, Paul G. Richardson, MD, Florence Magrangeas, Stephane Minvielle, PhD, Philippe Moreau, MD, Michel Attal, MD PhD, Anjan Thakurta, Kenneth C. Anderson, MD, Giovanni Parmigiani, PhD, Herve Avet-Loiseau, MD PhD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 3055.

DOI: https://doi.org/10.1182/blood-2019-128521

Published: 2019

Journal Articles

Lack of Significant Differences in Somatic Alterations between MGUS, SMM and Symptomatic Multiple Myeloma: A Result from Comprehensive Genomic Profiling Study

Anil Aktas Samur, PhD, Mariateresa Fulciniti, PhD, Raphael Szalat, Jill Corre, PharmD, PhD, Niccolo Bolli, MD PhD, Philippe Moreau, MD, Michel Attal, MD PhD, Kenneth C. Anderson, MD, Giovanni Parmigiani, PhD, Hervé Avet-Loiseau, MD PhD, Mehmet Kemal Samur, PhD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 3089.

DOI: https://doi.org/10.1182/blood-2019-128570

Published: 2019

Journal Articles

High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma

Brief Report

Anjan Thakurta, Maria Ortiz, Pedro Blecua, Fadi Towfic, Jill Corre, Natalya V. Serbina, Erin Flynt, Zhinuan Yu, Zhihong Yang, Antonio Palumbo, Meletios A. Dimopoulos, Norma C. Gutierrez, Hartmut Goldschmidt, Pieter Sonneveld, Herve Avet-Loiseau

Blood (2019) 133 (11): 1217–1221.

DOI: https://doi.org/10.1182/blood-2018-10-880831

Published: 2019

Includes: Supplemental data

Journal Articles

Variable BCL2/BCL2L1 ratio in multiple myeloma with t(11;14)

Clinical Trials & Observations

Alice Cleynen, Mehmet Samur, Aurore Perrot, Laure Buisson, Sabrina Maheo, Mariateresa Fulciniti, Michel Attal, Nikhil Munshi, Hervé Avet-Loiseau, Jill Corre

Blood (2018) 132 (26): 2778–2780.

DOI: https://doi.org/10.1182/blood-2018-09-876433

Published: 2018

Journal Articles

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Clinical Trials & Observations

Blood (2018) 132 (23): 2456–2464.

DOI: https://doi.org/10.1182/blood-2018-06-858613

Published: 2018

Includes: Supplemental data

Journal Articles

Minimal Residual Disease in Multiple Myeloma: Final Analysis of the IFM2009 Trial

Hervé Avet-Loiseau, MD PhD, Valerie Lauwers-Cances, MD, Jill Corre, PharmD, PhD, Philippe Moreau, MDPhD, Michel Attal, MD PhD, Nikhil Munshi, MD

Blood (2017) 130 (Supplement 1): 435.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.435.435

Published: 2017

Journal Articles

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma

CME

Blood (2016) 128 (25): 2941–2948.

DOI: https://doi.org/10.1182/blood-2016-07-726778

Published: 2016

NARROW

Upfront Carfilzomib, Lenalidomide, Dexamethasone with Transplant in Multiple Myeloma Patients, the IFM KRd final results

del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma

Risk factors in multiple myeloma: is it time for a revision?

Undetectable MRD can change the deal

Longitudinal Immunogenomic Profiling of Tumor and Immune Cells for Minimally-Invasive Monitoring of Smoldering Multiple Myeloma (SMM): The Immunocell Study

High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma

High Throughput Genomic Analysis Identifies Low-Risk Smoldering Multiple Myeloma

The Genomic and Transcriptomic Landscape of Plasma Cell Leukemia

Genomic and Transcriptomic Characterization of IgM Multiple Myeloma Identifies a Pre-Germinal Center Plasma Cell Disorder with Immature B-Cell Transcription-Factor Signature

Minimal Residual Disease in Multiple Myeloma: Targeted Mass Spectrometry in Blood Vs Next Generation Sequencing in Bone Marrow

The Discriminatory Ability of the R-ISS Is Equivalent to the ISS in a Large Cohort of Newly Diagnosed Multiple Myeloma (NDMM) Patients

Crowded bone marrow plasma cells

Gene Expression and Genomic Markers Identify a Subpopulation of Poor Prognosis t(4;14) Patients in Newly Diagnosed Multiple Myeloma

The Landscape of Genome Wide Somatic Alterations Identifies a Good-Risk Group in Newly Diagnosed Multiple Myeloma

Lack of Significant Differences in Somatic Alterations between MGUS, SMM and Symptomatic Multiple Myeloma: A Result from Comprehensive Genomic Profiling Study

High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma

Variable BCL2/BCL2L1 ratio in multiple myeloma with t(11;14)

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Minimal Residual Disease in Multiple Myeloma: Final Analysis of the IFM2009 Trial

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only